Sartorius (SRT.DE) Stock Price
Sartorius Price
Over the last 19 years Sartorius grew revenue by 10.6% annually, reaching 3.54 B EUR. Earnings per share have grown at 9.1% per year over the last 19 years. For Sartorius, the net margin of 4.4% is down versus 12.4% a few years ago. At today's price the dividend yield works out to roughly 0.66%. The payout ratio is around 33% of earnings. The dividend has grown at 14.1% per year over the past 19 years. The consensus 12-month price target for Sartorius is 266.22 EUR, about 16.3% above where the stock trades today. Of 8 analysts, 6 rate the stock a buy — an overall Buy consensus.
Sartorius stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Sartorius business model & stock analysis
Frequently asked questions about Sartorius
The business model of Sartorius AG, a renowned company in the stock market, revolves around providing innovative and high-quality products and solutions for biopharmaceutical research and manufacturing. Sartorius AG specializes in the fields of laboratory instruments, consumables, and services, catering to the needs of pharmaceutical and biotech companies worldwide. With a strong focus on bioprocessing technologies, Sartorius AG enables its customers to efficiently develop and produce medications. Through continuous advancements in technology and a customer-oriented approach, Sartorius AG has established itself as a leading supplier in the life science industry, contributing significantly to the advancement of healthcare.
Sartorius AG is primarily active in the life sciences industry.
The main competitors of Sartorius AG in the market include Thermo Fisher Scientific, Danaher Corporation, and Merck KGaA.
Sartorius AG is a renowned German company with a rich history and background. Founded in 1870, Sartorius specializes in manufacturing and distributing laboratory and process technologies. With a strong focus on biopharmaceutical research and production, the company is widely recognized for its innovative solutions in filtration, weighing, and separation technologies. Sartorius AG has expanded globally and established a strong presence in over 110 countries, catering to a diverse range of industries such as food, healthcare, and biotechnology. With a legacy of excellence, Sartorius AG continues to be a leading provider of cutting-edge scientific instruments and services.
Sartorius AG, a renowned company in the stock market, has accomplished several significant milestones. With a strong focus on precision and excellence, Sartorius AG has achieved remarkable growth and recognition over the years. Some noteworthy achievements include expanding its global presence by establishing subsidiaries and offices in key markets, continuously innovating and launching breakthrough products, and solidifying strategic partnerships with leading industry players. Sartorius AG has also received prestigious awards for its cutting-edge technology and outstanding performance in the life sciences and biopharmaceutical sectors. Through its dedication to quality and customer satisfaction, Sartorius AG has established itself as a trusted and forward-thinking company in the stock market.
Sartorius AG, a leading biotechnology and laboratory equipment provider, is primarily present in various countries and regions worldwide. The company's global footprint extends across major markets, including North America, Europe, Asia-Pacific, and Latin America. With its headquarters in Goettingen, Germany, Sartorius AG maintains a strong presence in its home country, serving as a hub for research and production. Moreover, the company has established subsidiaries and offices in key countries such as the United States, China, Japan, France, and many others, enabling Sartorius AG to cater to a diverse customer base and foster strategic collaborations on a global scale.
Sartorius AG represents a set of values and corporate philosophy focused on innovation, quality, and sustainability. As a leading international laboratory and pharmaceutical equipment provider, Sartorius AG ensures customer satisfaction by continually developing cutting-edge technologies and maintaining the highest standards of product excellence. With a strong commitment to sustainability, the company aims to create long-term value for its stakeholders, including customers, employees, and investors. Sartorius AG's dedication to ethical practices, collaboration, and social responsibility underpins its mission to contribute to the progress of science and the betterment of society.
Analysts currently set an average price target of 302.69 EUR for the Sartorius stock (median: 266.22 EUR), implying +32.2 % versus the latest price. The consensus is based on 8 analyst ratings.
8 analysts currently rate the Sartorius stock: 6 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Sartorius to generate revenue of 3.73 B EUR and earnings per share of 5.29 EUR.
The Sartorius share (SRT.DE) is listed on 10 stock exchanges, including: London (0NIQ.L), SIX (Zürich) (SRT.SW), XETRA (SRT.DE), Frankfurt (SRT.F), München (SRT.MU), Düsseldorf (SRT.DU), Hamburg (SRT.HM).
Sartorius AG is a global provider of innovative technologies and solutions for biopharmaceuticals, as well as for laboratory, food, and environmental applications. The company has two divisions: Bioprocess Solutions and Lab Products & Services. Bioprocess Solutions supplies the necessary technologies and products for the production of biopharmaceuticals, including filtration systems, disposable bioreactors, peristaltic pumps, and process control systems. Lab Products & Services offers innovative laboratory instrumentation and consumables for research, development, quality assurance, and control. The company is known for its use of disposable systems in biopharmaceuticals, which ensure process sterility and reduce cleaning and validation efforts. The company is focused on innovation and customer orientation to remain competitive in a rapidly changing global market. It invests in research and development to offer the most future-proof and efficient technologies and solutions to its customers. Overall, Sartorius operates in a growing industry driven by an increase in global patient data, the rising demand for personalized medicine, and the need for more efficient production processes.
The expected revenue of Sartorius is 3.73 B EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Sartorius is 364.95 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Sartorius is currently 43.33. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Sartorius stock.
The price-to-sales ratio (P/S) of Sartorius is currently 4.24. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Sartorius stock.
The Eulerpool Quality Score for Sartorius is 3/10.
The ISIN of Sartorius is DE0007165607. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Sartorius is 716560. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Sartorius is SRT.DE. The ticker symbol is used to trade Sartorius shares on the stock exchange.
Sartorius stock
Sartorius Peer Group
Sartorius Ticker
Sartorius FIGI
All fundamentals and in-depth analysis of Sartorius
Our stock analysis for Sartorius stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sartorius. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.